A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: Non-steroidal anti-inflammatory drugs

Clinical and Experimental Rheumatology

Volumn 27, Issue 4 SUPPL. 55, 2009, Pages

  Poddubnyy, Denis A ^a   Song, In Ho ^a   Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Ankylosing spondylitis; NSAID; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETORICOXIB; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PLACEBO; ROFECOXIB; TUMOR NECROSIS FACTOR INHIBITOR;

ADVERSE OUTCOME; AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC PAIN; CLINICAL TRIAL; COMORBIDITY; CORTICOSTEROID THERAPY; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LOW BACK PAIN; LOW DRUG DOSE; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SHORT COURSE THERAPY; STOMACH OBSTRUCTION; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE INHIBITORS; DISEASE PROGRESSION; HUMANS; SPONDYLITIS, ANKYLOSING;

EID: 71249126146     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. VANE JR, BAKHLE YS, BOTTING RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
2. CUSH JJ, LIPSKY PE: Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum 1988; 31: 1230-1238
3. CUSH JJ, LIPSKY PE, POSTLETHWAITE AE, SCHROHENLOHER RE, SAWAY A, KOOPMAN WJ: Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum 1990; 33: 19-28.
4. CUSH JJ, JASIN HE, JOHNSON R, LIPSKY PE: Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal antiinflammatory drugs. Arthritis Rheum 1990; 33: 623-633
5. GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS: 2002 Update. Arthritis Rheum 2002; 46: 328-346
6. SIMON LS, WEAVER AL, GRAHAM DY et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921-1928
7. ZHAO SZ, HECHTNER JI, TINDALL EA et al.: Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib. Arthritis Care Res 2000; 13: 112-121 (Pubitemid 30751833)
8. FURST DE, KOLBA KS, FLEISCHMANN R et al.: Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol 2002; 29: 436-446
9. COLLANTES E, CURTIS SP, LEE KW et al.: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract 2002; 3: 10.
10. MATSUMOTO AK, MELIAN A, MANDEL DR et al.: A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002; 29: 1623-1630 (Pubitemid 34831233)
11. MATSUMOTO A, MELIAN A, SHAH A, CURTIS SP: Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial. Curr Med Res Opin 2007; 23: 2259-2268
12. EMEA press release (2 August 2005). Available at: http://www.emea.europa. eu/pdfs/human/press/pr/24732305en.pdf [Last accessed 5 July 2009].
13. US Food and Drug Administration web site. Proposed NSAID Package Insert Labeling Template. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm106230.pdf [Last accessed 5 July 2009].
14. SINGH G, TRIADAFILOPOULOS G: Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999; 56: 18-24.
15. CRYER B: Nonsteroidal anti-inflammatory drug gastrointestinal toxicity. Curr Opin Gastroenterol 2001 Nov; 17: 503-512
16. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528
17. GOLDSTEIN JL, CORREA P, ZHAO WW et al.: Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96: 1019-1027
18. LAINE L, CURTIS SP, CRYER B, KAUR A, CANNON CP: Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465-473
19. SCHNITZER TJ, BURMESTER GR, MYSLER E et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-674
20. SONG IH, PODDUBNYY DA, RUDWALEIT M, SIEPER J: Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 2008 Mar 27; 58: 929-938
21. GABRIEL SE, JAAKKIMAINEN L, BOMBARDIER C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-796
22. BRESALIER RS, SANDLER RS, QUAN H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102 (Pubitemid 40365350)
23. KEARNEY PM, BAIGENT C, GODWIN J, HALLS H, EMBERSON JR, PATRONO C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-1308
24. FOSBOL EL, GISLASON GH, JACOBSEN S et al.: Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 190-197
25. NURMOHAMED MT: Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009; 8: 663-667
26. CANNON CP, CURTIS SP, FITZGERALD GA et al.: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771-1781
27. FARKOUH ME, GREENBERG JD, JEGER RV et al.: Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 2007; 66: 764-770
28. ZOCHLING J, VAN DER HEIJDE D, BURGOS-VARGAS R et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-52.
29. BRAUN J, DAVIS J, DOUGADOS M, SIEPER J, VAN DER LINDEN S, VAN DER HEIJDE D: First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316-320
30. DOUGADOS M, GUEGUEN A, NAKACHE JP et al.: Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford). 1999; 38: 235-244
31. BARKHUIZEN A, STEINFELD S, ROBBINS J, WEST C, COOMBS J, ZWILLICH S: Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 2006; 33: 1805-1812
32. VAN DER HEIJDE D, BARAF HS, RAMOS-REMUS C et al.: Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205-1215
33. SIEPER J, KLOPSCH T, RICHTER M et al.: Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 2008; 67: 323-329
34. AMOR B, DOUGADOS M, LISTRAT V et al.: Are classification criteria for spondylarthropathy useful as diagnostic criteria? Rev Rhum Engl Ed 1995; 62: 10-15
35. ANDERSON JJ, BARON G, VAN DER HEIJDE D, FELSON DT, DOUGADOS M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-1886
36. BOERSMA JW: Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol 1976; 5: 60-64
37. WANDERS A, HEIJDE D, LANDEWÉ R et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52: 1756-1765
38. RUDWALEIT M, NIEWERTH M, LISTING J et al.: Disease activity over one year in early ankylosing spondylitis in a prospective observational cohort (GESPIC). Ann Rheum Dis 2005; 64 (Suppl. III): 65 [Abstract OP0027].
39. GOSSEC L, DOUGADOS M, PHILLIPS C et al.: Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis 2008; 67: 782-788